Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Alnylam (Group)

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. ONPATTRO, available in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, is Alnylam’s first U.S. FDA-approved RNAi therapeutic. Alnylam has a deep pipeline of investigational medicines, including three product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 800 people worldwide and is headquartered in Cambridge, MA. *


Period Start 2002-01-01 established
Products Industry RNAi technology
  Industry 2 RNAi drug (RNAi therapeutic)
Region Region Cambridge, MA
  Country United States (USA)
  Street 300 Third Street
  City 02142 Cambridge, MA
  Tel +1-617-551-8200
    Address record changed: 2020-12-02
Basic data Employees E: 501 to 1,000 (2018-08-29)
  Currency USD
  Annual sales 50,900,000 (revenue, consolidated (2007) 2007-12-31)
  Profit -85,500,000 (2007-12-31)
  Cash 443,873,000 (2008-03-31)
    * Document for �About Section�: Alnylam Pharmaceuticals, Inc.. (8/29/18). "Press Release: Alnylam to Webcast Presentations at Upcoming September Investor Conferences". Cambridge, MA.
Record changed: 2020-02-19


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Alnylam (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top